The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Alafi Christopher D since 2005.
This trader's CIK number is 1299430.
At the time of last reporting, Alafi Christopher D was the Director of Intra-cellular Therapies, Inc.. (stock ticker symbol ITCI).
Also see all insider trading activities at Intra-cellular Therapies, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | ITCI | 0 | $0 | 27,675 | $1,119,490 | 0 | $0 |
| 2020 | ITCI | 70,500 | $2,054,880 | 0 | $0 | 0 | $0 |
| 2019 | ITCI | 880,000 | $9,151,370 | 0 | $0 | 0 | $0 |
| 2017 | ITCI | 268,065 | $4,155,507 | 0 | $0 | 0 | $0 |
| 2016 | ITCI | 99,000 | $1,550,463 | 0 | $0 | 0 | $0 |
| 2014 | ITCI | 53,320 | $791,372 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2013 | STXS | 0 | $0 | 261,241 | $976,869 | 261,241 | $878,031 |
| 2012 | STXS | 8,674,908 | $0 | 0 | $0 | 0 | $0 |
| 2011 | STXS | 150,000 | $301,144 | 0 | $0 | 0 | $0 |
| 2010 | STXS | 76,000 | $325,829 | 0 | $0 | 0 | $0 |
| 2009 | STXS | 95,000 | $330,551 | 0 | $0 | 0 | $0 |
| 2008 | STXS | 1,089,643 | $4,951,403 | 0 | $0 | 0 | $0 |
| 2007 | STXS | 10,000 | $108,900 | 0 | $0 | 0 | $0 |
| 2005 | STXS | 24,702 | $179,043 | 0 | $0 | 0 | $0 |
1. Intra-cellular Therapies, Inc. (ITCI)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-05-21 | ITCI | Sale | 1,100 | 40.00 | 44,000 |
| 2021-05-24 | ITCI | Sale | 26,575 | 40.47 | 1,075,490 |
| 2020-09-14 | ITCI | Buy | 49,500 | 29.60 | 1,465,200 |
| 2020-09-11 | ITCI | Buy | 21,000 | 28.08 | 589,680 |
| 2019-09-10 | ITCI | Buy | 485,000 | 10.04 | 4,868,430 |
| 2019-08-30 | ITCI | Buy | 125,000 | 8.52 | 1,065,250 |
| 2019-06-12 | ITCI | Buy | 170,000 | 11.54 | 1,961,290 |
| 2019-05-14 | ITCI | Buy | 100,000 | 12.56 | 1,256,400 |
| 2017-11-22 | ITCI | Buy | 10,000 | 15.55 | 155,500 |
| 2017-10-02 | ITCI | Buy | 258,065 | 15.50 | 4,000,007 |
| 2016-12-07 | ITCI | Buy | 20,826 | 16.14 | 336,048 |
| 2016-12-06 | ITCI | Buy | 44,174 | 16.33 | 721,449 |
| 2016-11-14 | ITCI | Buy | 34,000 | 14.50 | 492,966 |
| 2014-12-01 | ITCI | Buy | 1,422 | 14.75 | 20,974 |
| 2014-11-28 | ITCI | Buy | 35,000 | 14.75 | 516,250 |
| 2014-11-19 | ITCI | Buy | 1,034 | 14.25 | 14,734 |
| 2014-11-18 | ITCI | Buy | 3,531 | 14.23 | 50,246 |
| 2014-11-14 | ITCI | Buy | 133 | 15.07 | 2,004 |
| 2014-11-11 | ITCI | Buy | 5,000 | 15.55 | 77,750 |
| 2014-11-12 | ITCI | Buy | 5,000 | 15.23 | 76,150 |
| 2014-11-13 | ITCI | Buy | 2,200 | 15.12 | 33,264 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2013-08-16 | STXS | Option Ex | 261,241 | 3.36 | 878,031 |
| 2013-08-19 | STXS | Sale | 239,021 | 3.74 | 894,655 |
| 2013-08-20 | STXS | Sale | 22,220 | 3.70 | 82,214 |
| 2012-05-10 | STXS | Buy | 8,674,908 | .00 | 0 |
| 2011-09-12 | STXS | Buy | 64,468 | 1.34 | 86,387 |
| 2011-09-09 | STXS | Buy | 35,532 | 1.33 | 47,257 |
| 2011-06-03 | STXS | Buy | 50,000 | 3.35 | 167,500 |
| 2010-08-18 | STXS | Buy | 26,000 | 3.25 | 84,500 |
| 2010-03-02 | STXS | Buy | 19,800 | 4.83 | 95,614 |
| 2010-03-03 | STXS | Buy | 30,200 | 4.83 | 145,715 |
| 2009-08-26 | STXS | Buy | 30,000 | 3.49 | 104,730 |
| 2009-05-29 | STXS | Buy | 15,000 | 3.44 | 51,600 |
| 2009-05-13 | STXS | Buy | 41,463 | 3.49 | 144,581 |
| 2009-05-14 | STXS | Buy | 8,537 | 3.47 | 29,640 |
| 2008-12-29 | STXS | Buy | 1,012,130 | 4.64 | 4,696,283 |
| 2008-11-20 | STXS | Buy | 10,000 | 3.52 | 35,250 |
| 2008-11-18 | STXS | Buy | 44,075 | 3.56 | 156,730 |
| 2008-11-17 | STXS | Buy | 22,338 | 2.65 | 59,173 |
| 2008-03-14 | STXS | Buy | 1,100 | 3.61 | 3,967 |
| 2007-03-15 | STXS | Buy | 10,000 | 10.89 | 108,900 |
| 2005-12-06 | STXS | Buy | 23,393 | 7.26 | 169,763 |
| 2005-12-05 | STXS | Buy | 1,309 | 7.09 | 9,280 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Alafi Christopher D (Director of Intra-cellular Therapies, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.